CN100558350C - 改良透皮递药系统 - Google Patents

改良透皮递药系统 Download PDF

Info

Publication number
CN100558350C
CN100558350C CNB038184397A CN03818439A CN100558350C CN 100558350 C CN100558350 C CN 100558350C CN B038184397 A CNB038184397 A CN B038184397A CN 03818439 A CN03818439 A CN 03818439A CN 100558350 C CN100558350 C CN 100558350C
Authority
CN
China
Prior art keywords
tds
medicine
amine functions
substrate
functions medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB038184397A
Other languages
English (en)
Chinese (zh)
Other versions
CN1671365A (zh
Inventor
M·汉奈
D·W·沙赫特
H·-M·沃尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Publication of CN1671365A publication Critical patent/CN1671365A/zh
Application granted granted Critical
Publication of CN100558350C publication Critical patent/CN100558350C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038184397A 2002-07-30 2003-07-28 改良透皮递药系统 Expired - Lifetime CN100558350C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016864A EP1386604A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system
EP02016864.7 2002-07-30

Publications (2)

Publication Number Publication Date
CN1671365A CN1671365A (zh) 2005-09-21
CN100558350C true CN100558350C (zh) 2009-11-11

Family

ID=30011092

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038184397A Expired - Lifetime CN100558350C (zh) 2002-07-30 2003-07-28 改良透皮递药系统

Country Status (21)

Country Link
EP (2) EP1386604A1 (https=)
JP (1) JP4837915B2 (https=)
KR (1) KR101016914B1 (https=)
CN (1) CN100558350C (https=)
AT (1) ATE343380T1 (https=)
AU (1) AU2003266252B2 (https=)
BR (1) BR0313092A (https=)
CA (1) CA2490573C (https=)
CY (1) CY1105878T1 (https=)
DE (1) DE60309329T2 (https=)
DK (1) DK1524971T3 (https=)
ES (1) ES2273042T3 (https=)
IL (1) IL165917A (https=)
MX (1) MXPA05000349A (https=)
NO (1) NO334187B1 (https=)
NZ (1) NZ537476A (https=)
PL (1) PL376999A1 (https=)
PT (1) PT1524971E (https=)
SI (1) SI1524971T1 (https=)
WO (1) WO2004012719A1 (https=)
ZA (1) ZA200500255B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP5546013B2 (ja) * 2008-02-27 2014-07-09 久光製薬株式会社 貼付剤及び包装体
EP2258369B1 (en) * 2008-02-27 2015-04-08 Hisamitsu Pharmaceutical Co., Inc. Medicated patch
US9925150B2 (en) * 2009-12-22 2018-03-27 Lts Lohmann Therapie-Systeme Ag Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
EP3016641B1 (de) 2013-07-03 2018-09-05 LTS Lohmann Therapie-Systeme AG Transdermales therapeutisches system mit elektronischem bauteil
EP3145502B1 (en) 2014-05-20 2022-07-06 LTS Lohmann Therapie-Systeme AG Transdermal delivery system containing rotigotine
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1089469A (zh) * 1992-10-05 1994-07-20 天鹅治疗体系公司 用于持续释放药物的传送装置的二相基材
CN1182358A (zh) * 1995-04-26 1998-05-20 瑟垃技术有限公司 透皮促进剂甘油三醋酸酯
CN1462185A (zh) * 2001-05-08 2003-12-17 施瓦茨制药有限公司 用于治疗帕金森氏病的改良经皮治疗系统
CN1295470C (zh) * 1999-06-22 2007-01-17 扎纳西电机公司 由供电频率可变的电动机驱动的致冷压缩机

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
JP2002045699A (ja) * 2000-08-08 2002-02-12 Mitsubishi Electric Corp 排ガス浄化用層状電気化学触媒
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
ATE364380T1 (de) * 2001-03-16 2007-07-15 Alza Corp Transdermales pflaster zur verabreichung von fentanyl
CA2441064A1 (en) * 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1089469A (zh) * 1992-10-05 1994-07-20 天鹅治疗体系公司 用于持续释放药物的传送装置的二相基材
CN1182358A (zh) * 1995-04-26 1998-05-20 瑟垃技术有限公司 透皮促进剂甘油三醋酸酯
CN1295470C (zh) * 1999-06-22 2007-01-17 扎纳西电机公司 由供电频率可变的电动机驱动的致冷压缩机
CN1462185A (zh) * 2001-05-08 2003-12-17 施瓦茨制药有限公司 用于治疗帕金森氏病的改良经皮治疗系统

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Controlled Transdermal Delivery of Fentanyl,Characterizationsof Pressure -Sensitive Adhesives for MatrixPatch Design. Roy,Samir D et al.J.Phar.Sci,Vol.85 No.5. 1996 *

Also Published As

Publication number Publication date
ZA200500255B (en) 2006-01-25
MXPA05000349A (es) 2005-03-31
DE60309329T2 (de) 2008-04-17
DE60309329D1 (de) 2006-12-07
ES2273042T3 (es) 2007-05-01
PT1524971E (pt) 2007-01-31
AU2003266252A1 (en) 2004-02-23
WO2004012719A1 (en) 2004-02-12
NO20050770L (no) 2005-02-11
CY1105878T1 (el) 2011-02-02
CA2490573C (en) 2011-06-07
KR101016914B1 (ko) 2011-02-22
CN1671365A (zh) 2005-09-21
NO334187B1 (no) 2014-01-13
AU2003266252B2 (en) 2008-11-20
BR0313092A (pt) 2005-06-21
CA2490573A1 (en) 2004-02-12
IL165917A (en) 2007-07-24
PL376999A1 (pl) 2006-01-23
SI1524971T1 (sl) 2007-02-28
JP2005535686A (ja) 2005-11-24
HK1083458A1 (zh) 2006-07-07
DK1524971T3 (da) 2007-02-19
ATE343380T1 (de) 2006-11-15
KR20050025638A (ko) 2005-03-14
JP4837915B2 (ja) 2011-12-14
IL165917A0 (en) 2006-01-15
EP1386604A1 (en) 2004-02-04
EP1524971A1 (en) 2005-04-27
NZ537476A (en) 2007-08-31
EP1524971B1 (en) 2006-10-25

Similar Documents

Publication Publication Date Title
US8617591B2 (en) Transdermal delivery system for the administration of rotigotine
JP5564469B2 (ja) ロチゴチン投与のための改善された経皮送達系
US8246980B2 (en) Transdermal delivery system
CN100558350C (zh) 改良透皮递药系统
PL193074B1 (pl) Transdermalny system terapeutyczny zawierający agonistę D2 i sposób wytwarzania tego systemu
HK1062649A (en) Improved transdermal delivery system
HK1083458B (en) Improved transdermal delivery system
HK1062650A (en) Improved transdermal delivery system for the administration of rotigotine
HK1083459A (en) Improved transdermal delivery system for the administration of rotigotine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083458

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1083458

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: UCB PHARMA. CO., LTD.

Free format text: FORMER NAME: SCHWARZ PHARMA AG

CP01 Change in the name or title of a patent holder

Address after: German Monheim

Patentee after: UCB PHARMA GmbH

Address before: German Monheim

Patentee before: Schwarz Pharma AG

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20091111